ESMO Congress 2026: ctDNA Analysis Reveals Genomic Features Linked to Early Lorlatinib Progression in ALK-Positive NSCLC

New translational data from the Phase III CROWN trial, presented at the ESMO Congress 2026, indicates that early progression on lorlatinib in previously untreated ALK-positive advanced non-small cell lung cancer (NSCLC) is associated with greater baseline genomic complexity, higher blood-based tumor mutational burden, more frequent TP53 alterations, and enrichment of inflammatory-response pathways. This analysis helps clarify why a minority of patients do not experience prolonged benefit from lorlatinib, which otherwise shows exceptional long-term disease control.

Context

Lorlatinib is a targeted therapy used for treating ALK-positive advanced NSCLC, a subtype of lung cancer. The Phase III CROWN trial has previously shown that lorlatinib can provide long-term disease control for many patients. However, a subset of patients experiences early progression, prompting the need for further investigation into the underlying causes.

Why it matters

Understanding the genomic features linked to early progression on lorlatinib is crucial for improving treatment strategies for ALK-positive NSCLC. This research highlights the need for personalized approaches in cancer therapy. It also sheds light on why some patients do not respond well to a drug that generally offers significant benefits.

Implications

Patients with high genomic complexity and specific mutations may require alternative treatment strategies earlier in their care. This research could lead to more tailored therapies that improve outcomes for those at risk of early progression. On a broader scale, it may influence clinical guidelines and the development of new drugs targeting specific genomic alterations.

What to watch

Future studies may focus on developing predictive biomarkers based on the genomic features identified in this analysis. Monitoring how these findings influence treatment protocols for ALK-positive NSCLC will be important. Additionally, the ongoing response from the medical community regarding these insights could shape future research directions.